Researchers at the Department of Psychiatry at the University of North Carolina – Chapel Hill, in collaboration with Electromedical Products International, Inc. (EPI), have made a significant breakthrough in treating depression with a non-invasive brain stimulation technology. The technology works by delivering personalized brain stimulation based on real-time measurements of brain activity, targeting a specific electric activity pattern disrupted in major depressive disorder. An initial clinical trial published in the American Journal of Psychiatry showed an 80% reduction in symptom severity for patients with major depressive disorder after just five daily sessions.
Dr. Flavio Frohlich, Professor of Psychiatry at UNC – Chapel Hill, described the results as “stunning” and a potential “game changer” for millions of patients seeking better treatment options for their depression symptoms. The success of the targeted electric brain activity modulation in reducing symptoms offers a promising new approach to treating depression. EPI’s device adjusts the electric waveform delivered to the patient based on the brain’s response during each session, engaging in a dialogue with the brain.
Dr. Leah Townsend, Chief Science Officer of EPI, expressed excitement about the promising results and plans to move forward with a double-blind, placebo-controlled study of the technology. Brian Burke, President of EPI, highlighted the potential market impact of their closed-loop brain stimulation technology and their dedication to innovation. EPI is a leading neuromodulation therapeutic company specializing in non-invasive brain stimulation for psychiatric disorders and insomnia. This breakthrough in depression treatment showcases the potential impact of their technology in the medical field.
Source
Photo credit www.biospace.com